Year: 1999
Type: dissertation
Abstract: Buprenorphine is a promising medication for the treatment of opiate abuse.The pharmacology of buprenorphine has been studied in vitro using radioligand binding and e 5 S]GTPyS assays, and in vivo using assays of antinociception in rodents.A number of compounds with potential similar pharmacology have also been characterised.These are an iso-morphinan pyrrolidine derivative, and long-lasting 14-aminomorphinones and codeinones, in particular clocinnamox (C-CAM), a pure !!antagonist and methoclocinnamox (MC-CAM), which has some agonist properties.Buprenorphine, a partial !!-agonist and K-antagonist, displays a unique bell-shaped dose-response curve in assays of antinociception in rodents.Pre-treatment of rats with the antagonist naltrexone shifted the ascending, but not the descending, phase of the dose-response curve.Investigation of the time-course of various doses of buprenorphine revealed that higher doses produced a rapid on-and offset of analgesia compared to lower doses, and this may explain the bell-shaped dose-response curve.The morphinan-pyrrolidine derivative, BUn, is shown to be a highly efficacious !!-opioid agonist in C6 glioma cells transfected with the cloned l1-opioid receptor.In the mouse warm water tail withdrawal assay Bun was 400 times more potent than morphine, and considerably longer-lasting.Bun exhibited delayed !!-antagonist action in both the warm water tail withdrawal and writhing assays, blocking the effects of a maximal dose of morphine for up to 2 weeks in the writhing assay.This compound may represent an improvement over buprenorphine for the treatment of opiate abuse.MC-CAM and a series of 3-substituted alkyl ether derivatives showed varymg efficacy in SH-SY5Y human neuroblastoma cells.All displayed high affinity for the !!-opioid receptor and with the exception of the iso-propyl ether, BU25, all the analogues displayed biphasic'binding profiles.BU25 was shown to be fully reversible in wash resistance assays.The results support 'pseudoirreversible' binding of these compounds to the !!-opioid receptor.Further in vitro studies of C-CAM confirmed !!-antagonist action but have also shown it to be an inverse agonist at the O-opioid receptor.Also identified as inverse agonists were 7-benzylidenenaltrexone (BNTX), and the peptide ICI 174,864.Treatment of C6 glioma cells with' pertussis toxin confirmed the presence of constitutive activity at the &but not the Il-receptor.C-CAM did not inhibit basal e 5 S]GTPyS binding in C61l or C6 wild-type cells.
Author: Brett A. Neilan
Institution: Loughborough University
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W827900373
